← Leaderboards
Ebru Oral
Massachusetts General Hospital
$1,845,345
Attributed
$1,845,345
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $393.8K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,845,345 · 1
By mechanism
R01$1,845,345 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Daniel S Kohane$17,057,196
- Jose M Teixeira$9,923,155
- Paula I Watnick$19,648,431
- Allen C Steere$11,999,334
- Lida P Hariri$6,583,581
Others in their field
Other Emerging Leaders on “Design”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- John E West · University Of Texas At Austin$113,883,001
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Kevin Urdahl · Seattle Children'S Hospital$72,239,698
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
Research focus
DesignCrosslinkCostAntibioticsComplicationAnalgesicsControlled ReleaseCommunicable DiseasesArthrodesisAttentionAlternative TreatmentAntimicrobialBiomedical EngineeringBiometryAnti-Bacterial AgentsAmputationBupivacaineAntioxidantsCaringChemotherapyClinical DevelopmentClinically RelevantBacterial InfectionsDevices
Grant awards (5)
Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testing$356,247
R01 · FY2024 · AR · contact PI
Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testing$367,366
R01 · FY2023 · AR · contact PI
Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testing$363,789
R01 · FY2022 · AR · contact PI
Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testing$364,184
R01 · FY2021 · AR · contact PI
Drug-eluting joint implants with synergistic antimicrobial release and risk stratified models of preclinical efficacy testing$393,759
R01 · FY2020 · AR · contact PI